EUVIMEDEUVIMED entdecken
Crossref

Performance of a sirolimus-eluting balloon with phospholipid nanocarriers in the treatment of long de novo coronary artery disease: the prospective GINGER trial

Alfonso Ielasi, Mauro Gitto, Stefano Galli, Giuseppe Massimo Sangiorgi, Rodolfo Caminiti, Pier Pasquale Leone, Antonio Mangieri, Gerlando Preti, Francesco Grigioni, Matteo Montorfano, Maurizio Tespili, Antonio Colombo

Clinical Research in Cardiology · 04.08.2026

DOI: 10.1007/s00392-026-02997-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 04.08.2026. Verfasst von Alfonso Ielasi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unità Operativa di Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Via Belgioioso 173, 20157, Milan, Italy. alfonso.ielasi@gmail.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sirolimus-coated balloons (SCB) may offer improved antiproliferative efficacy over paclitaxel-coated balloons; however, data regarding their performance in de novo coronary lesions are limited.

Objectives

The GINGER study aimed to evaluate the angiographic efficacy and clinical safety of a SCB (Magic Touch®) in the treatment of long (≥ 25 mm) de novo coronary artery lesions.

Methods

This observational, prospective, multicenter, single-arm cohort study enrolled patients with at least one long de novo lesion treated with SCB. Co-primary endpoints were late lumen loss (LLL) and net lumen gain at 9 months. Secondary endpoints included: procedural success, periprocedural myocardial infarction, binary restenosis and a device-oriented composite endpoint (DOCE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI) and clinically-driven target lesion revascularization (CD-TLR). The study was registered at ClinicalTrials.gov (NCT05471245).

Results

A total of 104 patients was enrolled at 8 centers. Mean lesion length was 28.9 ± 16.0 mm and reference vessel diameter was 2.3 ± 0.6 mm. Procedural success was achieved in all cases. At 9-month angiographic follow-up, LLL was 0.28 ± 0.68 mm, net lumen gain 0.62 ± 0.63 mm, and binary restenosis was observed in 33.3% of lesions. Clinical events at 12-month included DOCE in 6.7% of patients, cardiac death in 1.0%, TV-MI in 4.8% and CD-TLR in 3.8%. No lesion thrombosis was reported.

Conclusions

In a real-world cohort of patients with long de novo coronary lesions, the Magic Touch SCB was associated with a LLL of 0.28 mm, which should be interpreted in light of the high complexity of treated lesions. Future randomized trials are warranted to evaluate its clinical efficacy in comparison with new-generation drug-eluting stents. Graphical abstract Abbreviations: ACS, acute coronary syndrome; CD-TLR, clinically-driven target lesion revascularization; CV, cardiovascular; CTO, chronic total occlusion; DOCE, device-oriented composite endpoint; LLL, late lumen loss; RVD, reference vessel diameter; SCB, sirolimus-coated balloon; TV-MI, target vessel myocardial infarction.

Schlagwörter

Stichwörter der Autor:innen

De novoAngioplastyCoronary artery diseaseDrug-coated balloonLong vessel diseaseSirolimus

Autor:innen und Institutionen

  • Unità Operativa di Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Via Belgioioso 173, 20157, Milan, Italy. alfonso.ielasi@gmail.com.
  • IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.
  • Cardiologia Invasiva 2, Centro Cardiologico Fondazione Monzino, IRCCS, Università di Milano, Milan, Italy.
  • Department of Biomedicine and Prevention, University of Rome ''Tor Vergata'', Rome, Italy.
  • Unità Operativa di Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Via Belgioioso 173, 20157, Milan, Italy.

Zitieren

APA

Ielasi, A., Gitto, M., Galli, S., Sangiorgi, G. M., Caminiti, R., Leone, P. P., Mangieri, A., Preti, G., Grigioni, F., Montorfano, M., Tespili, M., & Colombo, A. (2026). Performance of a sirolimus-eluting balloon with phospholipid nanocarriers in the treatment of long de novo coronary artery disease: the prospective GINGER trial. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-02997-1

Vancouver

Ielasi A, Gitto M, Galli S, Sangiorgi GM, Caminiti R, Leone PP, et al. Performance of a sirolimus-eluting balloon with phospholipid nanocarriers in the treatment of long de novo coronary artery disease: the prospective GINGER trial. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-02997-1

BibTeX
@article{Ielasi2026,
  author = {Ielasi, Alfonso and Gitto, Mauro and Galli, Stefano and Sangiorgi, Giuseppe Massimo and Caminiti, Rodolfo and Leone, Pier Pasquale and Mangieri, Antonio and Preti, Gerlando and Grigioni, Francesco and Montorfano, Matteo and Tespili, Maurizio and Colombo, Antonio},
  title = {Performance of a sirolimus-eluting balloon with phospholipid nanocarriers in the treatment of long de novo coronary artery disease: the prospective GINGER trial},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-026-02997-1}
}
Kostenlos starten →